Abstract:Rationale and Objectives: The aim of the study was to determine whether myocardial fibrosis parameters of cardiac magnetic resonance imaging (MRI) has added value in the risk stratification of hypertrophic cardiomyopathy (HCM) patients. Materials and Methods: In this retrospective study, 108 patients with HCM (mean age +/- standard deviation, 55.5 +/- 13.4 years) were included from January 2019 to April 2022, and were followed up for 2 years to record sudden cardiac death (SCD) adverse events. All HCM patients underwent cardiac MRI and were divided into a training cohort (n = 81; mean age, 56.1 +/- 13.0 years) and a validation cohort (n = 27; mean age, 57.8 +/- 13.9 years). According to the presence of SCD risk factors defined by the 2020 AHA/ACC guidelines, HCM patients were classified into low-risk and high-risk groups. Cardiac MRI features, including late gadolinium enhancement (LGE), T1 mapping, and extracellular volume fraction (ECV), were assessed and compared between the two groups. Logistic regression analysis was used to select the optimal predictors of SCD from cardiac MRI features and HCM Risk-SCD score to construct prediction models. Receiver operating curve (ROC) analysis was used to assess the predictive performance of the constructed prediction model. Cox regression analysis was also used to determine the optimal predictors of SCD adverse events. Results: Multivariate logistic analysis showed that the global ECV was the single myocardial fibrosis parameter predictive of the risk of SCD (p < 0.001). The areas under the ROC curves (AUC) of global ECV were higher than those of LGE, global native T1, global postcontrast T1, and HCM Risk-SCD (AUC = 0.85 vs. 0.74, 0.77, 0.63, 0.78). An integrative risk stratification model combining global ECV (odds ratio, 1.36 [95% CI: 1.16-1.60]; p < 0.001) and HCM Risk-SCD score (odds ratio, 1.63 [95% CI: 1.08-2.47]; p < 0.001) achieved an AUC of 0.89 (95% CI: 0.81-0.96) in the training cohort, which was significantly higher than that of HCM Risk-SCD score alone (p = 0.03). The AUC of the integrative model was 0.93 (95% CI: 0.84-1.00) in the validation cohort. Multivariate Cox regression analysis also showed that the global ECV was an independent predictor of SCD adverse events (hazard ratio, 1.27 [95% CI: 1.10-1.47]). Conclusion: The ECV derived from cardiac MRI is comparable to the HCM Risk-SCD scale in predicting the SCD risk stratification in patients with HCM.

Predictors of late gadolinium enhancement in hypertrophic cardiomyopathy by electrocardiogram and echocardiography

Relation of Late Gadolinium Enhancement in Cardiac Magnetic Resonance on the Diastolic Volume Recovery of Left Ventricle with Hypertrophic Cardiomyopathy.

Relation Of Late Gadolinium Enhancement In Cardiac Magnetic Resonance On The Diastolic Volume Recovery Of Left Ventricle With Hypertrophic Cardiomyopathy (Vol 6, Pg 988, 2014)

Evaluation of left ventricular myocardial strain of patients with hypertrophic cardiomyopathy using cardiac magnetic resonance imaging

B-PO03-165 MEAN SCAR ENTROPY PREDICTS VENTRICULAR ARRHYTHMIAS EVENTS IN HYPERTROPHIC CARDIOMYOPATHY USING LATE GADOLINIUM ENHANCEMENT CARDIAC MAGNETIC RESONANCE

Predictive values of multiple non-invasive markers for myocardial fibrosis in hypertrophic cardiomyopathy patients with preserved ejection fraction

Predictive Value of Cardiac Magnetic Resonance Mechanical Parameters for Myocardial Fibrosis in Hypertrophic Cardiomyopathy with Preserved Left Ventricular Ejection Fraction.

Relationship between Extension or Texture Features of Late Gadolinium Enhancement and Ventricular Tachyarrhythmias in Hypertrophic Cardiomyopathy

Additional Prognostic Values of Strain and Strain Rate over Late Gadolinium Enhancement in Hypertrophic Cardiomyopathy Patients

Prognostic value of myocardial extracellular volume fraction evaluation based on cardiac magnetic resonance T1 mapping with T1 long and short in hypertrophic cardiomyopathy

Assessment and Regression Analysis of Left Ventricular Mass with Cardiovascular Magnetic Resonance in Patients of Hypertrophic Cardiomyopathy

Myocardial Contraction Fraction as a Simple Marker of Disease Severity in Hypertrophic Cardiomyopathy

Refining risk stratification in hypertrophic cardiomyopathy: the role of late gadolinium enhancement and syncope in predicting adverse outcomes

Global Circumferential Strain by Cardiac Magnetic Resonance Tissue Tracking Associated With Ventricular Arrhythmias in Hypertrophic Cardiomyopathy Patients

Early marker of regional left ventricular deformation in patients with hypertrophic cardiomyopathy evaluated by MRI tissue tracking: The effects of myocardial hypertrophy and fibrosis

Incremental value of myocardial global longitudinal strain in predicting major adverse cardiac events among patients with hypertrophic cardiomyopathy

Association between late gadolinium enhancement and outcome in dilated cardiomyopathy: A meta-analysis

Focal ischemic myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy

Left Ventricular Strain Patterns and Their Relationships with Cardiac Biomarkers in Hypertrophic Cardiomyopathy Patients with Preserved Left Ventricular Ejection Fraction

The Value of Myocardial Fibrosis Parameters Derived from Cardiac Magnetic Resonance Imaging in Risk Stratification for Patients with Hypertrophic Cardiomyopathy

Diffusion-weighted imaging in hypertrophic cardiomyopathy: association with high T2-weighted signal intensity in addition to late gadolinium enhancement